GlassScriptPhysician profile
Sean J Brimacombe
NPI 1427105048
$107,191.15
in general payments reported to CMS, 2019-2025
27 companies · $528 in 2025
The $528 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $7,005 · 2021: $8,031 · 2022: $2,962 · 2023: $47.68 · 2024: $1,329 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210 · Travel and Lodging: $696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.60 |
| Travel and Lodging | $695.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $91,081.81 | 2019-2025 | Evenity |
| Heron Therapeutics, INC. | $5,647.75 | 2019 | |
| Smith+Nephew, INC. | $4,350.63 | 2019-2023 | Collagenase Santyl |
| Ucb Sa | $2,760.00 | 2021 | |
| Mimedx Group, INC. | $1,345.65 | 2024-2025 | |
| Radius Health, INC. | $597.05 | 2019-2022 | |
| Ucb, INC. | $296.26 | 2019-2022 | |
| Kerecis Limited | $203.95 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Davol INC. | $138.73 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $121.76 | 2025 | Lynparza |
| Biosense Webster, INC. | $118.08 | 2019 | |
| Kci USA, INC. | $82.78 | 2019-2021 | |
| Team_makena_llc | $77.17 | 2019 | |
| Wright Medical Technology, INC. | $42.15 | 2019 | |
| Depuy Synthes Sales INC. | $35.32 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $32.46 | 2020 | |
| Misonix INC | $29.86 | 2020 | |
| Organogenesis INC. | $28.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.05 | 2019-2020 | |
| Integra Lifesciences Corporation | $25.39 | 2019-2023 | Tcc-Ez |
| Musculoskeletal Transplant Foundation INC. | $24.99 | 2019-2021 | |
| Urgo Medical North America, LLC | $24.42 | 2024 | Urgoclean Ag |
| Mallinckrodt Enterprises LLC | $23.68 | 2019 | |
| Polarityte, INC. | $20.96 | 2019 | |
| Solventum Corporation | $18.54 | 2024 | Activ.A.C. |
| Acera Surgical, INC. | $18.50 | 2020 | |
| Paratek Pharmaceuticals, INC. | $18.42 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Brimacombe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.